The development of a GeXP-based multiplex reverse transcription-PCR assay for simultaneous detection of sixteen human respiratory virus types/subtypes by unknown
RESEARCH ARTICLE Open Access
The development of a GeXP-based multiplex
reverse transcription-PCR assay for simultaneous
detection of sixteen human respiratory virus
types/subtypes
Jin Li1†, Nai-Ying Mao1†, Chen Zhang1, Meng-Jie Yang1, Miao Wang1, Wen-Bo Xu1* and Xue-Jun Ma1*
Abstract
Background: Existing standard non-molecular diagnostic methods such as viral culture and immunofluorescent
(DFA) are time-consuming, labor intensive or limited sensitivity. Several multiplex molecular assays are costly.
Therefore, there is a need for the development of a rapid and sensitive diagnosis of respiratory viral pathogens.
Methods: A GeXP-based multiplex RT-PCR assay (GeXP assay) was developed to detect simultaneously sixteen
different respiratory virus types/subtypes. Seventeen sets of chimeric primers were used to initiate the RT-PCR, and
one pair of universal primers was used for the subsequent cycles of the RT-PCR. The specificity of the GeXP assay
was examined with positive controls for each virus type/subtype. The sensitivity was evaluated by performing the
assay on serial ten-fold dilutions of in vitro-transcribed RNA of all RNA viruses and the plasmids containing the Adv
and HBoV target sequence. GeXP assay was further evaluated using 126 clinical specimens and compared with
Luminex xTAG RVP Fast assay.
Results: The GeXP assay achieved a sensitivity of 20–200 copies for a single virus and 1000 copies when all of the
16 pre-mixed viral targets were present. Analyses of 126 clinical specimens using the GeXP assay demonstrated that
GeXP assay and the RVP Fast assay were in complete agreement for 109/126 (88.51%) of the specimens. GeXP assay
was more sensitive than the RVP Fast assay for the detection of HRV and PIV3, and slightly less sensitive for the
detection of HMPV, Adv, RSVB and HBoV. The whole process of the GeXP assay for the detection of 12 samples was
completed within 2.5 hours.
Conclusions: In conclusion, the GeXP assay is a rapid, cost-effective, sensitive, specific and high throughput
method for the detection of respiratory virus infections.
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Background
Viral respiratory tract infections, which have a consider-
able morbidity and fatality rate, are common diseases
that especially affect infants and the elderly [1]. Common
respiratory viruses include influenza A virus, influenza B
virus, parainfluenza virus, human rhinovirus, adenovirus
and respiratory syncytial virus. New respiratory viruses
important to public health, such as metapneumovirus,
coronavirus (subtypes SARS-Cov and CoV HKU1) and
human bocavirus [2,3], have emerged over the past dec-
ade. The clinical presentation of respiratory infections
caused by different viral pathogens can be very similar,
making etiological diagnosis difficult [4].
The traditional assays used to diagnose respiratory
tract viruses are viral culture and immunofluorescent
staining. Viral culture remains the gold standard for the
diagnosis of respiratory viruses because of its broad
spectrum and high specificity. However, viral culture is
time-consuming and has a low sensitivity for the
* Correspondence: wenbo_xu1@yahoo.com.cn; maxj2004@yahoo.com.cn
†Equal contributors
1State Key Laboratory for Molecular Virology and Genetic Engineering,
National Institute for Viral Disease Control and Prevention, Chinese Center for
Disease Control and Prevention, Changbai Rd 155, Beijing, Changping District
102206, China
© 2012 Li et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Li et al. BMC Infectious Diseases 2012, 12:189
http://www.biomedcentral.com/1471-2334/12/189
detection of some respiratory viruses that have fastidious
growth requirements [5,6]. Immunofluorescent staining
is fast, but the assay sensitivity and the availability of
antisera can be limiting factors [5,6]. With the develop-
ment of rapid molecular techniques, molecular assays,
especially in a multiplex format, have been accepted as
tests of choice for broad spectrum detection of respira-
tory viruses. Several multiplex assays are available com-
mercially such as xTAG RVP from Luminex [7,8],
Multicode-PLx RVP from EraGen Biosciences [9], and
ResPlex II from Qiagen [10]. However, all of them are
based on a liquid-phase bead-based array technology to
implement the detection, which has increased the cost
and the implementation time of the whole assays.
The GenomeLab Gene Expression Profiler genetic
analysis system (GeXP) developed by Beckman Coulter
(Brea, CA, USA) is a new multitarget, high-throughput
detection platform that integrates reverse transcription-
PCR (RT-PCR) and labeled amplified products in a
multiplex PCR assay, followed by fluorescence capillary
electrophoresis separation based on the size of the amp-
lified products. This system has been used previously in
identifying rapidly gene expression prostate cancer bio-
marker signatures in biological samples, rapid and sensi-
tive detection of 68 unique varicella zoster virus gene
transcripts [11] and detection of pandemic influenza A
H1N1 virus [12] and nine serotypes of enteroviruses
associated with hand, foot and mouth disease [13].
In this report, a novel RT-PCR assay using the GeXP
(GeXP assay) for rapid, sensitive, multiplex detection of
sixteen different respiratory virus types/subtypes: influ-
enza A virus (FluA), influenza B virus (FluB), seasonal in-
fluenza A H1N1 virus (sH1N1), parainfluenza virus type
1 (PIV1), parainfluenza virus type 2 (PIV2), parainfluenza
virus type 3 (PIV3), human rhinovirus (HRV), human
metapneumovirus (HMPV), adenovirus (Adv), respira-
tory syncytial virus A (RSVA), respiratory syncytial virus
B (RSVB), four coronavirus sybtypes (CoV HKU1, CoV
NL63, CoV 229E, CoV OC43) and human bocavirus
(HBoV) was described. The specificity and sensitivity of
the GeXP assay were examined, and the clinical perform-
ance of the GeXP assay was evaluated by comparing the
results obtained by the GeXP assay to those obtained by
the Luminex xTAG RVP Fast kit (Luminex Corporation,
Toronto, Canada) for 126 nasopharyngeal aspirates col-
lected from hospitalized children.
Methods
Viruses and controls
Cell culture virus stocks from the NATtrolTM Respiratory
Validation Panel 2 (NATRVP-2) (ZeptoMetrix, New
York, USA) were used as the positive controls for FluA
H3, FluB, sH1N1, PIV1-3, HRV, Adv 3, RSVA, RSVB,
HMPV, CoV 229E and CoV OC43. Clinical specimens
that were genotyped and sequenced previously by the
Biotech Center for Viral Disease Emergency, a part of
the Chinese Center for Disease Control (CCDC), were
used as positive controls for HBoV, CoV HKU1 and
CoV NL63.
To evaluate the sensitivity of the assay, controls were pre-
pared with dilutions from 10 to 105 copies of vectors con-
taining PCR products cloned from each virus individually.
The PCR products were cloned into a pGEM-T vector,
which was used to transform DH10B cells. The plasmid
DNA was extracted with an E.Z.N.A. Plasmid Mini Kit I
(Omega, GA, USA). The RNA copy number was calculated
after measuring the concentration of the RNA transcribed
in vitro using a T7 Large Scale RNA Production System
(Promega, Wisconsin, USA). For the DNA viruses Adv and
HBoV, the in vitro transcription was omitted.
Clinical specimens
A total of 126 nasopharyngeal aspirates were collected
from children under two years of age who were hospita-
lized at the Children’s Hospital of Beijing, China, during
June, 2008 and March, 2010 with a diagnosis of pneu-
monitis or bronchopneumonia and a fever of 38°C or
greater. A total volume of 0.5 ml of nasopharyngeal as-
pirate was collected in 3.5 ml of transport medium. This
study was approved by the Beijing ethics committee.
Sample collection was agreed by child's parents or
grandparents with informed consent.
Primer design
In total, 17 pairs of chimeric primers, one pair of internal
control primers and one pair of universal primers were
designed for the RT-PCR. The chimeric primers consisted
of a gene-specific sequence fused at the 5’ end to the uni-
versal sequence. The specific sequences were selected
by alignment of all sequences available for each virus
from the National Center for Biotechnology Informa-
tion (NCBI) GenBank Database. Primers for the human
RNase P gene were used as an internal control for the RT-
PCR of the clinical specimens. The forward universal
primer was Cy5-labeled at the 5’ end of the sequence.
The primers sequences, their target genes and the size
of the resulting amplicons are listed in Table 1 [14-16].
Extraction and purification of RNA/DNA
Total RNA/DNA was extracted from 200 μl of viral stocks
or clinical samples using the QIAamp Viral RNA Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions. The extracts was eluted in 50 μl of
DNase- and RNase-free water and stored at −80°C.
GeXP assay and detection
The multiplex RT-PCR was performed with a One Step
RT-PCR kit (Qiagen, Hilden, Germany) in a 25 μl
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volume, containing 5 μl of the 5× buffer, 1 μl of the
dNTP mix, 1 μl of the enzyme mix, 1.25 pmol each of
the forward chimeric primer mix and reverse chimeric
primer mix, 12.5 pmol each of the forward universal pri-
mer mix and reverse universal primer mix, 2 μl of tem-
plate RNA and 0.1 μl of ribonuclease inhibitor (Takara,
Dalian, China) and DNase- and RNase-free water. The
RT-PCR mixture was subjected to the following ampli-
fication conditions: 50°C for 30 min, 95°C for 15 min,
followed by 10 cycles of 95°C for 30 s, 55°C for 30 s,
72°C for 30 s; 10 cycles of 95°C for 30 s, 65°C for
30 s, 72°C for 30 s; 20 cycles of 95°C for 30 s, 48°C
for 30 s, 72°C for 30 s, and a final incubation of 72°C for
3 min. Two μl of each Cy5-labeled PCR product was
Table 1 Primer information
Primer Sequence 5’-3’ Gene Size (bp)
FluA F AGGTGACACTATAGAATATTCTAACCGAGGTCGAAACG M 270
FluA R GTACGACTCACTATAGGGAACAAAGCGTCTACGCTGCAG
FLuB F AGGTGACACTATAGAATAAAAAGRAGATTCATCACAGAGC M 166
FLuB R GTACGACTCACTATAGGGATTCTGCTATTTCAAATGCTTCA
sH1N1 F AGGTGACACTATAGAATAGGTATGCTTTTGCAMTGARTAGAGG HA 250
sH1N1 R GTACGACTCACTATAGGGAAAGGGATATTCCTTARTCCTGTARCCAT
PIV1 F AGGTGACACTATAGAATATCTCATTATTACCYGGACCAA HA 284
PIV1 R GTACGACTCACTATAGGGATCCTGTTGTCGTTGATGTCATA
PIV2 F AGGTGACACTATAGAATATCTACACTGCATCAGCCAGC HA 194
PIV2 R GTACGACTCACTATAGGGACCCCTAAAAGAGATGAGCCC
PIV3 F AGGTGACACTATAGAATATTGTCAATTATGATGGYTCAATCT HA 230
PIV3 R GTACGACTCACTATAGGGAGACACCCAGTTGTGTTGCAG
HRV F AGGTGACACTATAGAATACCCCTGAATGYGGCTAACCT 5' UTR 144
HRV R GTACGACTCACTATAGGGACGGACACCCAAAGTAGTYGGT
HMPV F1 AGGTGACACTATAGAATACATGCCCACTATAAAAGGTCAG L 208
HMPV R1 GTACGACTCACTATAGGGACACCCCAGTCTTTCTTGAAA
HMPV F2 AGGTGACACTATAGAATAGAGCTAAYAGAGTGCTAAGTGATG N 208
HMPV R2 GTACGACTCACTATAGGGAACTTTCTGCTTTGCTTCCTGT
Adv F AGGTGACACTATAGAATAGCCSCARTGGKCWTACATGCACATC Hexon 338
Adv R GTACGACTCACTATAGGGACAGCACSCCICGRATGTCAAA
NL63 F AGGTGACACTATAGAATATCCCAAATGTGATAGAGCTTTGC Polym-erase 176
NL63 R GTACGACTCACTATAGGGACTGTTAAAACTTGTGCCAACTC
OC43 F AGGTGACACTATAGAATAATTGCACCAGGAGTCCCA N 200
OC43 R GTACGACTCACTATAGGGATATCGGTGCCGTACTGGTCT
229E F AGGTGACACTATAGAATACTCGGAATCCTTCAAGTGACAGA N 183
229E R GTACGACTCACTATAGGGAACGAGAAGGCTTAGGAGTAC
HKU1 F AGGTGACACTATAGAATATATAGTRAAACCTGATATGGCT N 220
HKU1 R GTACGACTCACTATAGGGATACCAAAACACTGTTGAACAT
RSVA F AGGTGACACTATAGAATACATCCCCTCTATGCACAACC F 158
RSVA R GTACGACTCACTATAGGGACATGTTTCAGCTTGTGGGAA
RSVB F AGGTGACACTATAGAATAAAACGAAGATTTCTGGGCTTC F 279
RSVB R GTACGACTCACTATAGGGATGCGACAGCTCTGTTGATTT
HBoV F AGGTGACACTATAGAATAAAGAAAAGGGAGTCCAGAA NP1 290
HBoV R GTACGACTCACTATAGGGACTCTGTGTTGACTGAATACAG




a The primers HMPV F1 and HMPV R1 were reported previously [14]; the primers Adv F and Adv R were reported previously [15]; the primer HBoV R was reported
previously [16]. The Universal Tag sequences are underlined.
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separated via GeXP capillary electrophoresis, and the
dye signal strength was measured by fluorescence spec-
trophotometry in arbitrary units (A.U.) of optical fluor-
escence. For all amplified products, the reaction was
considered positive when the value of dye signal was
over 2000 A.U.
Specificity and sensitivity of the GeXP assay
The specificity of the GeXP assay for all viral targets was
tested individually in a multiplex assay under the experi-
mental conditions of the GeXP assay. The sensitivity of
the GeXP assay for all viral targets was examined indi-
vidually in a multiplex assay using serial ten-fold dilu-
tions from 10 to 105 copies of in vitro-transcribed RNA
of all RNA viruses and the plasmids containing the Adv
and HBoV target sequences. The sensitivity of the GeXP
assay was also examined by using 16 pre-mixed quanti-
tative viral targets.
RVP fast assay and detection
The Luminex xTAG RVP Fast kit (Luminex Corporation,
Toronto, Canada) enables users to detect simultaneously
FluA, FluB, RSV, PIV1-4, AdV, HMPV, CoV 229E, NL63,
OC43, and HKU1, enterovirus, HRV and HBoV. The
RNA/DNA extracted from 126 clinical specimens was
tested using the RVP Fast assay in a 96-well plate format
according to the manufacturer’s instructions (Luminex
Corporation, Toronto, Canada). The plate was then ana-
lyzed using the Bio-PlexTM 200 system (Bio-Rad, CA,
USA) according to the manufacturer’s instructions, and
the median fluorescence intensity (MFI) was determined.
Results
Specificity and sensitivity of the GeXP assay
The specificity of the GeXP assay for all viral targets was
tested individually in a multiplex assay. No mispriming
was observed when all 17 pairs of the chimeric primers
and one pair of the internal control primers were mixed
together. The specific products could be obtained and
separated clearly from the other viral targets on the
GeXP system for all of the positive controls (Figure 1.
A-P). For the viral targets that used clinical specimens
as positive controls, including HBoV, CoV HKU1, and
CoV NL63, a single PCR product was detected in
addition to the internal control peak. The dye signal in
the analysis was above 25000 A.U.
The sensitivity of the assay was evaluated individually
for each virus in the multiplex assay using serial ten-fold
dilutions of cloned PCR products. In the multiplex assay,
the detectable level of HRV and PIV2 was 20 copies per
reaction, while the limit of detection for the other 14
viruses types/subtypes was 200 copies per reaction. The
clones with the same copies of each virus were then pre-
mixed to evaluate the sensitivity when all of the 16 viral
targets were present. The detection sensitivity of all of
the pre-mixed viral targets was 1000 copies per reaction
in the multiplex assay (Figure 1. R).
Evaluation of the GeXP assay using respiratory specimens
All 126 specimens detected by the RVP Fast assay, the
reference method, were retested by the GeXP assay. The
results from both assays showed that HRV was found
most frequently (68/126), followed by RSVB (46/126)
and PIV3 (21/126) in the 126 specimens. A total of 23
negative specimens (18.25%) were detected by the GeXP
assay and 24 (19.05%) negative specimens by the RVP
Fast assay. One negative specimen detected by the RVP
Fast assay was found to be positive for HRV by the
GeXP assay. A total of 66 specimens with co-infections
were detected by the RVP Fast assay, 64 of them were co-
infections detected by the GeXP assay, and 4 additional
co-infections were detected only by the GeXP assay and
confirmed by sequencing as true positives.
The results from the GeXP assay and the RVP Fast
assay were in complete agreement for 109/126 (86.51%)
of the specimens. As shown in Table 2, there were 13
additional viruses (3 HRV, 3 RSVB, 2 HMPV, 1 Adv and
4 HBoV in 9 specimens) found only in the RVP Fast
assay and 9 viruses (6 HRV and 3 PIV3 in 8 specimens)
found only in the GeXP assay. All of the 9 additional
viruses detected only by the GeXP assay were confirmed
by sequencing as true positives. The results showed that
the GeXP assay was more sensitive than the RVP
Fast assay for the detection of HRV and PIV3, and
less sensitive for the detection of HMPV, Adv, RSVB
and HBoV. For RSVA, CoV, FluA, FluB, sH1N1,
PIV1, and PIV2, both the sensitivity and specificity
were 100%. The sensitivity, specificity, negative pre-
diction value (NPV) and positive prediction value
(PPV) of each virus, when compared to RVP Fast
assay as a reference, were calculated for the GeXP
assay in Table 2.
(See figure on previous page.)
Figure 1 Specificity and sensitivity analyses of the GeXP Assay. The Y-axis indicates the dye signal in arbitrary units, and the X-axis indicates
the actual PCR products size. Panels A-P show the results of amplification of FluA (H3N2), FluB, FluA (sH1N1), PIV1, PIV2, PIV3, HRV, HMPV, Adv,
RSVA, RSVB, HBoV, CoV OC43, CoV 229E, CoV NL63 and CoV HKU1, respectively. Nuclease-free water was used as a negative control (NC). All of
the 16 pre-mixed viral targets could be detected at the level of 1000 copies of each virus per reaction in the multiplex assay (R). The viral targets,
from left to right, are HRV, RSVA, FluB, CoV NL63, CoV 229E, PIV2, CoV OC43, HMPV, CoV HKU1, PIV3, sH1N1, FluA, RSVB, PIV1, HBoV and Adv (R).
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Discussion
A one-step, sensitive, specific assay using GeXP for the
simultaneous detection of 16 respiratory virus types/sub-
types (FluA, FluB, sH1N1,PIV1, PIV2, PIV3, HRV,
RSVA, RSVB, HMPV, Adv, CoV OC43, CoV 229E, CoV
NL63, CoV HKU1 and HBoV) was described in this study.
The GeXP genetic analysis system is a new multitarget,
high throughput detection platform, and its applica-
tion in the differential detection of pandemic Influenza
A H1N1 virus and seasonal Influenza A virus was reported
recently by our laboratory [12]. To further reduce the
assay time and avoid contamination, a one-step multitarget
RT-PCR was performed in one tube rather than multiplex
two-step RT-PCRs in separate tubes [12] would be pre-
ferred. To develop a one-step GeXP assay, several com-
mercial one-step RT-PCR kits from different companies
(Omega, Bio-Rad, Qiagen and Invitrogen) were tested in
our preliminary experiments. The one-step RT-PCR kit
from Qiagen revealed the best amplification to perform
under our current protocol (data not shown).
The temperature switch PCR (TSP) [17] strategy was
adopted to optimize the amplification parameters. The
biphasic PCR parameters of the TSP allow a multiplex
PCR to be performed under standardized PCR condi-
tions, and therefore do not require optimization of each
individual PCR assay. The optimal settings for three
different denaturation temperatures and the amplifica-
tion cycle conditions were determined in the current
protocol. The chimeric primers consisted of a specific
primer sequence fused to the universal primer sequence.
The primers were designed to generate gene fragments
with lengths between 140–340 bp. The amount of uni-
versal primers included in the RT-PCR was ten times
that of the chimeric primers, so in the last 20 cycles of
PCR, amplification was carried out predominantly by a
single pair of universal primers, of which only the for-
ward universal primer was labeled fluorescently. This
should reduce the occurrence of preferential amplifica-
tion in the reaction. Internal control primers were
added to the reaction to ascertain whether the extraction
and reverse-transcription steps of the assay were function-
ing correctly. Only 2 μl of the cy5-labeled PCR amplified
fragments were separated by capillary electrophoresis
based on size and detected by the GeXP system.
The specificity of the GeXP assay was examined using
artificial specimens from the NATRVP-2 panel and clin-
ical specimens confirmed previously to be positive. A
specific peak of PCR product was obtained only for the
expected viral target using the GeXP system. No cross-
reactivity among the 16 respiratory virus types/subtypes
was observed. The detection sensitivity for each virus
was 20–200 copies per reaction when the assay was
Table 2 Detection of 16 respiratory viruses in 126 specimens
Virus No. of specimens Performance of the GeXP assay
GeXP + a RVP + a GeXP + RVP - GeXP- RVP + GeXP-a RVP -a Sensitivity % Specificity % PPVa % NPVa %
FluA 5 0 0 121 100 100 100 100
sH1N1b 3 0 0 123 100 100 100 100
FluB 1 0 0 125 100 100 100 100
PIV1 1 0 0 125 100 100 100 100
PIV2 1 0 0 125 100 100 100 100
PIV3 21 3d 0 102 100 97.14 87.50 100
HRVc 68 6 3 49 95.77 89.09 91.89 94.23
HMPV 8 0 2 116 80.00 100 100 98.31
Adv 9 0 1 116 90.00 100 100 99.15
CoV NL63 1 0 0 125 100 100 100 100
CoV OC43 12 0 0 114 100 100 100 100
CoV 229E 2 0 0 124 100 100 100 100
CoV HKU1 4 0 0 122 100 100 100 100
RSVAb 2 0 0 124 100 100 100 100
RSVBb 46 0 3 77 93.88 100 100 96.25
HBoV 15 0 4 107 78.95 100 100 96.40
a The numbers of positive and negative specimens detected by the GeXP assay are indicated as GeXP + and GeXP -, respectively, and the numbers of positive
and negative specimens detected by the RVP Fast assay are indicated as RVP + and RVP -, respectively. The sensitivity (True positives, TP), specificity (True
negatives, TN), PPV (TP/TP + false positives), and NPV (TN/TN + false negatives) for each target are calculated using the RVP Fast assay as the reference for
comparison.
b The RVP Fast assay was able to subtype the FluA and RSV positive specimens.
c The RVP Fast assay was not able to distinguish rhinovirus from enterovirus, so ‘HRV’ positive detected by the RVP Fast assay could be HRV or enterovirus. All of
the specimens positive for HRV detected by the GeXP assay were confirmed by sequencing as true positives.
d All of the additional PIV3 detected only by the GeXP assay were confirmed by sequencing as true positives.
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performed separately for each virus, and the sensitivity
was 1000 copies per reaction when all of the 16 pre-
mixed viral targets were present in the multiplex assay.
The results indicate that the detection sensitivity of
the GeXP assay for mixed virus samples was slightly
lower than that for a single type of virus. The detection
sensitivity for each virus in this study was similar to
that of real-time PCR assays reported in recent years
[18-20].
Analyses of 126 specimens using the GeXP assay and
RVP Fast assay demonstrated that the GeXP assay had
comparable sensitivity and specificity to the commer-
cially available RVP Fast assay (Table 2). Discrepancies
in detection results were found for HRV, PIV3, HMPV,
Adv, RSV B and HBoV. All of the 9 specimens positive
for PIV3 or HRV detected only by the GeXP assay were
confirmed by independent PCR and sequencing to be
true positives (data not shown), suggesting that the
GeXP assay is more sensitive than the RVP Fast assay
for the detection of HRV and PIV3. Because the HRV
primers used in the RVP Fast assay were able to amplify
both HRV and enterovirus, the three specimens positive
for HRV detected only by the RVP Fast assay could actu-
ally be enteroviruses. All of the specimens positive for
HRV detected by the GeXP assay were confirmed by se-
quencing as true HRV positives. Two of HMPV negative
samples, 1 of Adv negative sample, 3 of RSVB negative
samples and 4 of HBoV negative samples detected by
the GeXP assay were positive by the RVP Fast assay. All
of these negative samples had lower median florescence
intensity (MFI) values (294–825) in the RVP Fast assay,
suggesting that the GeXP assay has a slightly decrease
sensitivity for the detection of HMPV, Adv, RSVB and
HBoV. However, the difference was not significant (for
HMPV, Adv, RSVB and HBoV, p = 0.5, 1, 0.25, 0.125, re-
spectively, using McNemar’s test; Kappa = 0.880, 0.943,
0.949, 0.864, respectively). The detection of corona-
viruses (CoV HKU1, CoV NL63, CoV 229E and CoV
OC43) by both assays was completely consistent between
assays. The overall detection rate of the GeXP assay
for each virus was comparable to that of the RVP Fast
assay, demonstrating the high sensitivity and specific-
ity of the GeXP assay in the analysis of clinical samples.
It should be noted that there are not sufficient positive
samples for FluA, sH1N1, FluB, PIV1,PIV2, CoV NL63,
CoV 229E, CoV HKU1 and RSVA to determine mean-
ingful statistics in our study. Due to the limited speci-
mens available at this time, only preliminary findings
were reported in this study. The detection rate for
infections involving two or more viruses was similar for
the GeXP assay (68/126) and the RVP Fast assay (66/
126). Most occurrences of multiplex infections involved
two of three viruses, HRV, RSVB and PIV3 (data not
shown).
Two distinct advantages of the GeXP assay are the
short assay time and the low cost per test. Though the
cost of GeXP equipment is approximately $100.000, the
cost of the GeXP assay for simultaneous detection of 16
respiratory virus types/subtypes is approximately $8 per
test (the RT-PCR kit and the consumables of detection),
versus $120 per test using the RVP Fast kit or $8 per test
for each virus using a commercial RT-PCR kit (DaAn,
Gene, China). The whole reaction was completed in one
tube in a one-step multiplex RT-PCR within 2.5 hours,
followed by capillary electrophoresis separation (10 min/
12 wells). In addition, two 96-well plates can be placed
in parallel in a GeXP machine at the same time to fur-
ther increase the throughput of the samples.
Conclusions
In summary, this study has demonstrated that the GeXP
assay is a rapid, cost-effective and high throughput
method with high sensitivity and specificity for the de-
tection of respiratory virus infection. Further validation
of the GeXP assay with a larger number of clinical sam-
ples is necessary before this method can be used widely
for routine laboratory testing in China.
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